FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965718993> ?p ?o ?g. }

• W1965718993 endingPage "15718" @default.
• W1965718993 startingPage "15709" @default.
• W1965718993 abstract "A hallmark of rheumatoid arthritis (RA) is the pseudo-tumoral expansion of fibroblast-like synoviocytes (FLSs), and the RA FLS has therefore been proposed as a therapeutic target. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been described as a pro-apoptotic factor on RA FLSs and, therefore, suggested as a potential drug. Here we report that exposure to TRAIL-induced apoptosis in a portion (up to 30%) of RA FLSs within the first 24 h. In the cells that survived, TRAIL induced RA FLS proliferation in a dose-dependent manner, with maximal proliferation observed at 0.25 nm. This was blocked by a neutralizing anti-TRAIL antibody. RA FLSs were found to express constitutively TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) on the cell surface. TRAIL-R2 appears to be the main mediator of TRAIL-induced stimulation, as RA FLS proliferation induced by an agonistic anti-TRAIL-R2 antibody was comparable with that induced by TRAIL. TRAIL activated the mitogen-activated protein kinases ERK and p38, as well as the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway with kinetics similar to those of TNF-α. Moreover, TRAIL-induced RA FLS proliferation was inhibited by the protein kinase inhibitors PD98059, SB203580, and LY294002, confirming the involvement of the ERK, p38, and PI3 kinase/Akt signaling pathways. This dual functionality of TRAIL in stimulating apoptosis and proliferation has important implications for its use in the treatment of RA. A hallmark of rheumatoid arthritis (RA) is the pseudo-tumoral expansion of fibroblast-like synoviocytes (FLSs), and the RA FLS has therefore been proposed as a therapeutic target. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been described as a pro-apoptotic factor on RA FLSs and, therefore, suggested as a potential drug. Here we report that exposure to TRAIL-induced apoptosis in a portion (up to 30%) of RA FLSs within the first 24 h. In the cells that survived, TRAIL induced RA FLS proliferation in a dose-dependent manner, with maximal proliferation observed at 0.25 nm. This was blocked by a neutralizing anti-TRAIL antibody. RA FLSs were found to express constitutively TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) on the cell surface. TRAIL-R2 appears to be the main mediator of TRAIL-induced stimulation, as RA FLS proliferation induced by an agonistic anti-TRAIL-R2 antibody was comparable with that induced by TRAIL. TRAIL activated the mitogen-activated protein kinases ERK and p38, as well as the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway with kinetics similar to those of TNF-α. Moreover, TRAIL-induced RA FLS proliferation was inhibited by the protein kinase inhibitors PD98059, SB203580, and LY294002, confirming the involvement of the ERK, p38, and PI3 kinase/Akt signaling pathways. This dual functionality of TRAIL in stimulating apoptosis and proliferation has important implications for its use in the treatment of RA. Rheumatoid arthritis (RA) 1The abbreviations used are: RA, rheumatoid arthritis; ERK, extracellular signal-regulated kinase; FCS, fetal calf serum; FLS, fibroblast-like synoviocyte; IL, interleukin; MAP, mitogen-activated protein; PBS, phosphate-buffered saline; PI3, phosphatidylinositol 3; RT, reverse transcription; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand. is an autoimmune disease characterized by chronic inflammation of joints leading to progressive and irreversible joint destruction. The aggressive front of synovial tissue, called pannus, invades and destroys local articular structure. The pannus is characterized by a synovial hyperplasia that is mainly composed of fibroblast-like synoviocytes (FLSs) combined with a massive infiltration of lymphocytes and macrophages. Both increased proliferation and/or insufficient apoptosis might contribute to the expansion of RA FLSs, and several reports suggest inducing apoptosis of RA FLSs as a therapeutic approach. Intraarticular expression of proinflammatory cytokines, in particular tumor necrosis factor (TNF)-α and IL-1β, plays a crucial role in the pathogenesis of RA (1Pope R.M. Nat. Rev. Immunol. 2002; 2: 527-535Crossref PubMed Scopus (329) Google Scholar). An anti-inflammatory role has been suggested for the TNF family member TRAIL (TNF-related apoptosis-inducing ligand) following the observations that the blockade of TRAIL in mice exacerbated autoimmune arthritis and that intraarticular TRAIL gene transfer relieved the symptoms (2Song K. Chen Y. Goke R. Wilmen A. Seidel C. Goke A. Hilliard B. J. Exp. Med. 2000; 191: 1095-1104Crossref PubMed Scopus (322) Google Scholar). In addition, one report described an increased sensitivity of TRAIL-deficient mice to collagen-induced arthritis (3Lamhamedi-Cherradi S.E. Zheng S.J. Maguschak K.A. Peschon J. Chen Y.H. Nat. Immunol. 2003; 4: 255-260Crossref PubMed Scopus (297) Google Scholar). TRAIL can interact with five different receptors, namely two agonistic receptors called DR4/TRAIL-R1 and DR5/TRAIL-R2 (hereafter referred to as TRAIL-R1 and -R2, respectively), two membrane-anchored decoy receptors designated DcR1/TRAIL-R3 and DcR2/TRAIL-R4 (hereafter referred to as TRAIL-R3, and -R4, respectively), and a soluble decoy receptor known as osteoprotegerin (OPG) (4Baetu T.M. Hiscott J. Cytokine Growth Factor Rev. 2002; 13: 199-207Crossref PubMed Scopus (92) Google Scholar). The physiological relevance of OPG as a receptor for TRAIL is unclear, because the affinity for this ligand at physiological temperatures has been described to be very low (5Truneh A. Sharma S. Silverman C. Khandekar S. Reddy M.P. Deen K.C. McLaughlin M.M. Srinivasula S.M. Livi G.P. Marshall L.A. Alnemri E.S. Williams W.V. Doyle M.L. J. Biol. Chem. 2000; 275: 23319-23325Abstract Full Text Full Text PDF PubMed Scopus (223) Google Scholar). Notably, the affinities of TRAIL-R3 and -R4 for TRAIL at physiological temperatures are ∼50–100-fold lower than those between TRAIL and its cognate receptors TRAIL-R1 and -R2 (5Truneh A. Sharma S. Silverman C. Khandekar S. Reddy M.P. Deen K.C. McLaughlin M.M. Srinivasula S.M. Livi G.P. Marshall L.A. Alnemri E.S. Williams W.V. Doyle M.L. J. Biol. Chem. 2000; 275: 23319-23325Abstract Full Text Full Text PDF PubMed Scopus (223) Google Scholar). The receptors TRAIL-R1 and -R2 contain a cytoplasmic death domain and can induce apoptosis through the activation of caspases upon ligation with a TRAIL ligand (reviewed in Ref. 6Wang S. El-Deiry W.S. Oncogene. 2003; 22: 8628-8633Crossref PubMed Scopus (702) Google Scholar). Nevertheless, the binding of TRAIL to these TRAIL receptors can also activate the transcription factor NFκB, which is known to control cell proliferation (7Schneider P. Thome M. Burns K. Bodmer J.L. Hofmann K. Kataoka T. Holler N. Tschopp J. Immunity. 1997; 7: 831-836Abstract Full Text Full Text PDF PubMed Scopus (599) Google Scholar). Indeed, although TRAIL is known to induce apoptosis in tumor cells (reviewed in Ref. 6Wang S. El-Deiry W.S. Oncogene. 2003; 22: 8628-8633Crossref PubMed Scopus (702) Google Scholar), TRAIL has also been shown to promote endothelial cell proliferation (8Secchiero P. Gonelli A. Carnevale E. Milani D. Pandolfi A. Zella D. Zauli G. Circulation. 2003; 107: 2250-2256Crossref PubMed Scopus (259) Google Scholar). Thus, depending on the cellular system, TRAIL is capable of initiating apoptosis or cell survival. The effect of TRAIL on the RA FLS appears to be controversial. Ichikawa et al. described TRAIL-R1 and -R2 expression on primary isolated FLSs from RA patients and reported that an agonistic anti-TRAIL-R2 antibody, as well as cross-linked TRAIL, induces apoptosis on these FLS (9Ichikawa K. Liu W. Fleck M. Zhang H. Zhao L. Ohtsuka T. Wang Z. Liu D. Mountz J.D. Ohtsuki M. Koopman W.J. Kimberly R. Zhou T. J. Immunol. 2003; 171: 1061-1069Crossref PubMed Scopus (94) Google Scholar). Similar observations have been reported by analyzing synovial fluid fibroblasts of RA patients (10Miranda-Carus M.E. Balsa A. Benito-Miguel M. De Ayala C.P. Martin-Mola E. Arthritis Rheum. 2004; 50: 2786-2793Crossref PubMed Scopus (39) Google Scholar). The conclusion that TRAIL induces apoptosis of the RA FLS was challenged previously by Perlman et al., who detected neither the expression of TRAIL-R1 and -R2 nor TRAIL susceptibility on primary isolated FLSs from RA patients (11Perlman H. Nguyen N. Liu H. Eslick J. Esser S. Walsh K. Moore T.L. Pope R.M. Arthritis Rheum. 2003; 48: 3096-3101Crossref PubMed Scopus (28) Google Scholar). Here we report for the first time that TRAIL can induce RA FLS proliferation in vitro through MAP kinases and PI3 kinase/Akt activation. Reagents—Recombinant human TNF-α was purchased from R&D Systems (Lille, France). Recombinant human IL-1β and recombinant human TRAIL were obtained from PeproTech (Rocky Hill, NJ). Polyclonal goat anti-TRAIL-R1, anti-TRAIL-R2, anti-TRAIL-R4, and mouse anti-TRAIL antibodies were purchased from R&D Systems. Control MOPC2.1 IgG was obtained from Sigma. Anti-phospho-ERK1/2 and anti-phospho-p38 (Thr(P)-180/Tyr(P)-182) were obtained from Upstate Biotechnology and BD Biosciences, respectively. The monoclonal mouse anti-phospho-Akt (Ser-473) antibody was obtained from Cell Signaling Technology (Beverly, MA). The rabbit polyclonal anti-NFκB p65 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), fluorescein isothiocyanate-conjugated secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, Pennsylvania), and peroxidase-conjugated secondary antibodies were purchased from Sigma. Preparation of Fibroblast-like Synoviocytes of Rheumatoid Arthritis Patients—Fibroblasts were isolated from synovium samples obtained from patients meeting the American College of Rheumatology criteria for RA (revised 1987) who had undergone surgery for synovectomy or total joint replacement surgery (12Arnett F.C. Edworthy S.M. Bloch D.A. McShane D.J. Fries J.F. Cooper N.S. Healey L.A. Kaplan S.R. Liang M.H. Luthra H.S. Medsger Jr., T.A. Mitchell D.M. Neustadt D.H. Pinals R.S. Schaller J.G. Sharp J.T. Wilder R.L. Hunder G.G. Arthritis Rheum. 1988; 31: 315-324Crossref PubMed Scopus (18640) Google Scholar). Fresh synovial tissues were minced and digested in a solution of dispase (Roche Applied Science), collagenase (Sigma), and DNase (Calbiochem). Synovial fibroblasts were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2 mm glutamine, 100 UI/ml penicillin, and 100 μg/ml streptomycin. The cells were used at passage 4–10, at which time they were a homogeneous population of fibroblasts. Upon reaching confluence, the cells were passaged by brief trypsinization as described previously (13Koch A.E. Polverini P.J. Leibovich S.J. Arthritis Rheum. 1986; 29: 471-479Crossref PubMed Scopus (107) Google Scholar). For enzyme-linked immunosorbent assay, Western blot, and reverse transcription (RT)-PCR experiments, RA FLSs were seeded in 6-well plates at 2 × 105 cells/well or in 6 cm-dishes at 4 × 105 cells. Fetal calf serum content of the media was progressively decreased from 10 to 1% with final starvation for 12 h in RPMI and 1% FCS. Cells were stimulated with TNF-α (2 nm), IL-1β (1 nm), or TRAIL (at indicated concentrations). Flow Cytometric Analysis—RA FLSs were harvested with Versene (Invitrogen) according to the manufacturer's instructions and suspended in PBS supplemented with 0.1% bovine serum albumin and 0.01% NaN3. Fifty to one hundred thousand cells were incubated for 20 min on ice in with 0.5 μg of goat anti-TRAIL-R1 antibody, anti-TRAIL-R2 antibody, anti-TRAIL-R4 antibody, or mouse anti-TRAIL antibody. As a negative control, cells were incubated with an isotype control antibody. Cells were then washed in fluorescence-activated cell sorter buffer and incubated for 20 min on ice with the corresponding fluorescein isothiocyanate-labeled anti-specie antibody. Viable cells were selected by propidium iodide exclusion, and analysis was performed using FACSCalibur (BD Biosciences). Cell Proliferation Assay—Proliferation was evaluated by measuring DNA synthesis through the incorporation of tritiated [3H]thymidine. FLSs were seeded in 96-well, flat-bottom culture plates at a density of 1 × 10 4 cells/well. Cells were cultured in RPMI with a decreasing concentration of FCS (10 and 5%) and then synchronized for 24 h with RPMI and 1% FCS. FLS were stimulated with various concentrations of TRAIL (0.25–10 nm) or media (RPMI/FCS (1%)) for 72 h. Every condition was tested in quadruplicate. [3H]thymidine (1 μCi/well) was added 18 h before the end of the assay. FLSs were lysed using a round of freeze-thaw cycle and then transferred onto a membrane filter using Harvester 96 (TOMTEC, Hamdem, CT). [3H]Thymidine incorporated into DNA was quantified using a scintillation counter 1450 MicroBeta Trilux (Wallac, Freiburg, Germany). For a competition assay, TRAIL at 0.5 nm was pre-incubated (30 min) with anti-TRAIL or MOPC2.1 IgG and added to cells. For experiments with protein kinases inhibitors, FLSs were preincubated for an hour with the specific inhibitors (or the solvent Me2SO alone) and then cultured with or without TRAIL (0.5 nm). Similar results were obtained using either synchronized cells (upon serum deprivation-induced growth arrest) or non-synchronized cells. Detection of Apoptosis—Cells were stimulated with TRAIL at 0.5 nm for indicated time points, and apoptosis was evaluated using annexin V binding and the uptake of TO-PRO-3 (Molecular Probes, The Netherlands). Briefly, 2–4 × 105 cells of RA FLS were collected and resuspended at 5–10 × 106 cells/ml in annexin V binding buffer. Then, 5–10 × 105 RA FLSs were incubated with 5 μl of annexin V-fluorescein isothiocyanate at 10 μg/ml (R&D systems) for 15 min at room temperature. Upon the addition of TO-PRO-3 (1:2000), cells were analyzed using FACSCalibur (BD Biosciences). RNA Isolation and cDNA Synthesis—Total RNA was isolated using the TRIzol reagent. Complementary DNA was synthesized by RT with SuperScript™ II RNase H– RT (Invitrogen). cDNA was obtained by RT of 1–4 μg of total mRNA, with oligo(dT)15 at 0.5 μg/μl as the primer, and the reaction was done according to the manufacturer's protocol (Invitrogen). RT-PCR—cDNA was screened for expression of human TRAIL employing the primers 5′-GTGTACTTTACCAACGAG-3′ (forward) and 5′-TTGCTCAGGAATGAATGC-3′ (reverse) generating a 391-bp fragment. The conditions used were 1 cycle at 94 °C for 5 min followed by 25–35 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. The products were resolved on a 1% agarose gel. RNA amounts varied from 100 to 400 ng for TRAIL and from 5 to 20 ng for β-actin. PCR was performed on ABI PRISM 7000 (Applied Biosystems, Courtaboeuf, France); signals were measured using Kodak 1D image analysis software, and each sample was normalized to β-actin level (with a forward primer of 5′-GCTGCTGACCGAGGCCCCCCTGAAC-3′ and a reverse primer of 5′-CTCCTTAATGTCACGCACGATTTC-3′ generating a 310-bp fragment). Western Blot Analysis—Synovial cells were stimulated, and the reaction was stopped on ice. Cells were washed twice with cold PBS and lysed with lysis buffer (100 mm Tris, pH 7.4, 100 mm NaCl, 1 mm EDTA, 1 mm NaF, 20 mm NaP2O7, 2 mm Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, and 0.5% desoxycholate). Cells were harvested with a cell scraper. For some experiments, cell extracts were sonicated and then centrifuged at 14,000 × g for 5 min. Protein concentrations were determined using BCA (Pierce), equal amounts of protein were resolved by SDS-PAGE (10 or 12% acrylamide), and immunoblot analysis was done as described previously (14Morel J.C. Park C.C. Zhu K. Kumar P. Ruth J.H. Koch A.E. J. Biol. Chem. 2002; 277: 34679-34691Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar). Blots were developed using a 1:1 mixture of coumaric acid (50 mm; Sigma) and luminol sodium salt (200 mm; Sigma). Blots were scanned, and densitometric signals were determined using Kodak 1D image analysis software. Data were expressed as arbitrary units after normalization to levels of β-actin. Immunofluorescence Staining—To determine the nuclear translocation of NFκB, RA FLSs were seeded at 2 ×104 cells/well in 8-well Lab-Tek chamber slides (Falcon). Cells were stimulated with TRAIL at 0.5 nm or with IL-1 at 1 nm for 30–120 min, washed with cold PBS, and then fixed in PBS with 4% paraformaldehyde for 20 min. Cells were permeabilized with PBS and 0.5% Triton X-100 for 10 min. Unspecific binding was prevented with blocking buffer containing 5% goat serum diluted in PBS. Cells were incubated with the rabbit polyclonal anti-NFκB p65 antibody (Santa Cruz Biotechnology) at 5 μg/ml or an isotype control for 60 min at room temperature. Cyan3-conjugated goat anti-rabbit antibody was used at 20 μg/ml for 60 min at room temperature. Coverslips were mounted with mounting media, and the subcellular localization of NFκB was visualized using a fluorescence microscope (Leica Microsystems, Heidelberg, Germany). Statistical Analysis—Results are expressed as the mean ± S.E. Statistical studies were performed with a non-parametric Wilcoxon test (Instat software). p values of <0.05 were considered statistically significant. TRAIL Induces Initially Apoptosis of RA FLS, but Proliferation of Surviving Cells—To test the effect of TRAIL on RA FLS, cells were co-cultured for 3 days with 0.5 nm TRAIL. The first 24 h of co-culturing with TRAIL resulted in apoptosis of ∼30% of the cells as determined by annexin V staining/TO-PRO-3 uptake (Fig. 1). This technique allows us to distinguish early apoptotic (annexin+/TO-PRO-3–) from late apoptotic cells (annexin+/TO-PRO-3+) (15Vermes I. Haanen C. Steffens-Nakken H. Reutelingsperger C. J. Immunol. Methods. 1995; 184: 39-51Crossref PubMed Scopus (4606) Google Scholar). As shown in Fig. 1, the highest percentage of early apoptotic cells was observed upon 4 h of TRAIL treatment. At later time points the cells shifted from the early apoptotic gate toward the late apoptotic cell gate. Apoptosis of RA FLS was also obvious in an analysis of forward angle light scatter (FSC; data not shown), because a decrease of FSC is characteristic of apoptotic cell death (15Vermes I. Haanen C. Steffens-Nakken H. Reutelingsperger C. J. Immunol. Methods. 1995; 184: 39-51Crossref PubMed Scopus (4606) Google Scholar). After 24 h of coculturing, ∼70% of RA FLSs were still viable. Similar results were obtained for RA FLSs derived from different patients (data not shown). Apoptotic cell numbers remained unchanged in unstimulated cells throughout the 72-h observation period (Fig. 1, left column). After 72 h of TRAIL exposure, proliferation of RA FLS was determined by [3H]thymidine incorporation (Fig. 2A). Significant increases in DNA synthesis were observed for all of the concentrations of TRAIL tested, with a maximum proliferation already detectable for 0.25 nm. TRAIL induced a 5-fold increase in RA FLS proliferation similar to that induced by the proinflammatory cytokine IL-1β (Fig. 2B). Simultaneous addition of TRAIL and IL-1β enhanced proliferation, demonstrating the additive effect of these two cytokines on RA FLS cells (Fig. 2B).Fig. 2Proliferation of fibroblast-like synoviocytes extracted from rheumatoid arthritis patients.A, TRAIL induces RA FLS proliferation in a dose-dependent manner. RA FLSs were stimulated for 72 h with the indicated concentrations of TRAIL, and proliferation was assessed using [3H]thymidine incorporation. B, additive effect of TRAIL combined with IL-1β on RA FLS proliferation. Cells were stimulated for 72 h with IL-1β (1 nm), TRAIL (0.5 nm), or the two cytokines combined. Proliferation was evaluated as described for panel A. C, the anti-TRAIL antibody inhibits TRAIL-induced RA FLS proliferation. TRAIL (0.5 nm) was pre-treated with anti-TRAIL antibody (0.5–1 μg/ml) or the control isotype-matched antibody MOPC2.1 IgG (1 μg/ml). Results represent the proliferation of RA FLS after 72 h upon treatment and are expressed as the stimulation index (the ratio of the arithmetic mean of counts per minute from the quadruplicate of stimulated culture to the arithmetic mean of counts per minute from the quadruplicate of non-stimulated culture). Data from the indicated number of patients (n) were averaged and shown as means ± S.E. NS, non-stimulated RA FLSs; asterisks (*), p values of <0.05.View Large Image Figure ViewerDownload Hi-res image Download (PPT) To confirm the specificity of TRAIL-induced proliferation, we evaluated the inhibitory effect of a neutralizing anti-TRAIL antibody. This led to an almost complete inhibition of TRAIL-mediated RA FLS proliferation, whereas the isotype control antibody had no effect (Fig. 2C). Treatment with either the anti-TRAIL antibody alone or the control antibody alone did not affect proliferation (data not shown). RA FLSs Express TRAIL mRNA and TRAIL-R1 and -R2 Proteins—We next analyzed the expression of TRAIL and its receptors in RA FLS. Semi-quantitative RT-PCR revealed the up-regulation of TRAIL mRNA expression by TNF-α and IL-1β by ∼2 and 5-fold, respectively, versus unstimulated cells (Fig. 3A). The TRAIL protein could not be detected either in soluble form in conditioned media or on the RA FLS cell surface (data not shown). This finding might be due to the limited sensitivity of the antibodies employed or a low translation efficiency. The expression of different TRAIL receptors on RA FLS was evaluated by flow cytometry. TRAIL-R1 and -R2 on RA FLSs were constitutively expressed, whereas TRAIL-R4 was not detectable (Fig. 3C). Expression of the receptors was unaltered when RA FLSs were treated with IL-1β, TNF-α, or TRAIL (data not shown). TRAIL-R2/DR5 Receptor Mediates TRAIL-induced Proliferation—Treatment of RA FLS with an agonistic anti-TRAIL-R2 antibody induced an ∼5-fold increase in RA FLS proliferation in comparison with untreated cells (Fig. 4). This increase corresponds to the maximal induction observed upon the addition of recombinant TRAIL (Fig. 4), suggesting that TRAIL-R2 mediates TRAIL-induced proliferation to a large extent. TRAIL Activates the Kinases p38, ERK1/2, and Akt but Not NFκB—To determine the intracellular mechanisms involved in TRAIL-induced cell proliferation, we tested the effect of TRAIL on signaling pathways that control cell proliferation, specifically those containing the MAP kinases p38 and ERK1/2 and PI3 kinase/Akt (16Franke T.F. Hornik C.P. Segev L. Shostak G.A. Sugimoto C. Oncogene. 2003; 22: 8983-8998Crossref PubMed Scopus (997) Google Scholar). RA FLSs were treated with 0.5 nm TRAIL and subsequently analyzed by Western blotting. Activating phosphorylation of p38 MAP kinase was rapidly induced by TRAIL and persisted up to 60 min, although with a lower intensity in comparison with that of TNF-α (Fig. 5, A and B). Treatment with TRAIL also induced activation of the phosphorylation of ERK1/2 and Akt in a time-dependent manner, with maximum activation occurring between 5 and 10 min (Figs. 5, C and D, and 6). The kinetics and intensities of ERK and Akt phosphorylation were comparable with those induced by TNF-α.Fig. 6TRAIL promotes Akt phosphorylation in the RA FLS.A and B, RA FLSs were treated as described in the Fig. 5 legend to assess Akt activation following TRAIL stimulation using an antibody specific for phosphorylated Akt. NS, non-stimulated.View Large Image Figure ViewerDownload Hi-res image Download (PPT) The transcription factor NFκB plays a major role in cell survival and can be activated by MAP kinases and Akt (17Reddy S.A. Huang J.H. Liao W.S. J. Biol. Chem. 1997; 272: 29167-29173Abstract Full Text Full Text PDF PubMed Scopus (219) Google Scholar, 18Firestein G.S. Manning A.M. Arthritis Rheum. 1999; 42: 609-621Crossref PubMed Scopus (178) Google Scholar). Upon activation, NFκB translocates from the cytoplasm to the nucleus, which can be visualized using indirect immunofluorescence (19May M.J. Ghosh S. Immunol. Today. 1998; 19: 80-88Abstract Full Text Full Text PDF PubMed Scopus (1051) Google Scholar). We therefore tested whether nuclear accumulation of NFκB could be detected in the RA FLS following TRAIL stimulation. Very little NFκB was in the nucleus in non-stimulated RA FLSs (4.3 ± 0.9%). IL-1β strongly induced its nuclear translocation (97.9 ± 1.1%). In contrast, only 6.7% (±1.2) of NFκB was nuclear upon exposure to TRAIL (Fig. 7, A and B). Western blotting confirmed these observations when NFκB was detectable in the nuclear fraction only upon TNF-α stimulation (Fig. 7C). Thus, the exposure of RA FLS to TRAIL activates the kinases p38 and ERK1/2 and PI3 but not the transcription factor NFκB. Akt, p38, and ERK Control TRAIL-mediated RA FLS Proliferation—To confirm that MAP kinases and PI3 kinase/Akt play a role in TRAIL-induced proliferation, we used the specific inhibitors LY294002 (PI3 kinase), PD98059 (ERK1/2), and SB203580 (p38). RA FLSs were pretreated with the specific inhibitors at different concentrations or with solvent (Me2SO) alone for 1 h and then stimulated with 0.5 nm TRAIL. Under these experimental conditions, cell viability was >90% (14Morel J.C. Park C.C. Zhu K. Kumar P. Ruth J.H. Koch A.E. J. Biol. Chem. 2002; 277: 34679-34691Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar). Proliferation was assessed by [3H]thymidine incorporation. ERK 1/2 inhibition (Fig. 8A) and p38 inhibition (Fig. 8B) significantly diminished TRAIL-induced proliferation in a dose-dependent manner. Strikingly, the PI3 kinase inhibitor almost completely blocked the proliferation induced by TRAIL, underlining the crucial role played by this pathway (Fig. 8C). The TRAIL ligand/receptor system has raised much interest for cancer therapy, because it appears to kill tumor cells but not normal ones (20Smyth M.J. Takeda K. Hayakawa Y. Peschon J.J. van den Brink M.R. Yagita H. Immunity. 2003; 18: 1-6Abstract Full Text Full Text PDF PubMed Scopus (287) Google Scholar). Fibroblast-like synoviocytes play a crucial role in the physiopathology of rheumatoid arthritis, as these cells are involved in inflammation and joint destruction. The pseudo-tumoral proliferation of RA FLS is considered to be the major mechanism for the hyperplasic growth of the RA synovium and can be mimicked by in vitro culturing, because ex vivo RA FLS cells grow in normal medium without requiring additional stimulation. RA FLSs exhibit certain tumor-like features, leading us to investigate the effect of TRAIL on RA FLS survival. Treatment of RA FLSs with TRAIL induced apoptosis within the first 24 h in ∼30% of the cells as detected by TO-PRO-3-uptake, annexin V staining, and decreased forward angle light scatter. Unexpectedly, TRAIL induced RA FLS proliferation in a dose-dependent manner at later culture times, i.e. 72 h. This was inhibited by neutralizing anti-TRAIL antibodies, confirming that cell proliferation is specifically induced by this cytokine. Moreover, combined stimulation with TRAIL and IL-1β had an additive effect on RA FLS proliferation, suggesting two independent mechanisms of stimulation. Further studies are required to analyze whether endogenous TRAIL participates in the pathogenesis of RA patients. The increased levels of TRAIL transcripts detected in RA FLS treated with proinflammatory cytokines argue for fratricide activation, but a contribution of TRAIL derived from synovial T cells is also possible. Our results suggest that TRAIL has two different effects on RA FLS, namely an initial rapid induction of apoptosis that is followed by an increased proliferation of the surviving population. These observations differ from those in the collagen-induced mouse model of arthritis that describes an inhibitory role for TRAIL by blocking the proliferation of synovial cells (2Song K. Chen Y. Goke R. Wilmen A. Seidel C. Goke A. Hilliard B. J. Exp. Med. 2000; 191: 1095-1104Crossref PubMed Scopus (322) Google Scholar, 3Lamhamedi-Cherradi S.E. Zheng S.J. Maguschak K.A. Peschon J. Chen Y.H. Nat. Immunol. 2003; 4: 255-260Crossref PubMed Scopus (297) Google Scholar). This discrepancy could reflect the different pathogenic mechanisms between RA in the joints of patients and the respective mouse model. Furthermore, only one membrane-anchored TRAIL receptor and two soluble decoy receptors have been identified in the mouse (21Schneider P. Olson D. Tardivel A. Browning B. Lugovskoy A. Gong D. Dobles M. Hertig S. Hofmann K. Van Vlijmen H. Hsu Y.M. Burkly L.C. Tschopp J. Zheng T.S. J. Biol. Chem. 2003; 278: 5444-5454Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar), indicating differences in the organization of TRAIL signaling between man and mouse. The name TRAIL derives from its capacity to induce apoptosis (22Wiley S.R. Schooley K. Smolak P.J. Din W.S. Huang C.P. Nicholl J.K. Sutherland G.R. Smith T.D. Rauch C. Smith C.A. Goodwin R.G. Immunity. 1995; 3: 673-682Abstract Full Text PDF PubMed Scopus (2656) Google Scholar). However, depending on the cellular system, TRAIL can exert different functions that also include survival, proliferation, and maturation. For example, TRAIL has been shown to promote cell survival and proliferation on endothelial and vascular smooth muscle cells (8Secchiero P. Gonelli A. Carnevale E. Milani D. Pandolfi A. Zella D. Zauli G. Circulation. 2003; 107: 2250-2256Crossref PubMed Scopus (259) Google Scholar, 23Secchiero P. Zerbinati C. Rimondi E. Corallini F. Milani D. Grill V. Forti G. Capitani S. Zauli G. Cell. Mol. Life Sci. 2004; 61: 1965-1974Crossref PubMed Scopus (119) Google Scholar) and to regulate erythroid and monocytic maturation (24Secchiero P. Melloni E. Heikinheimo M. Mannisto S. Di Pietro R. Iacone A. Zauli G. Blood. 2004; 103: 517-522Crossref PubMed Scopus (106) Google Scholar, 25Secchiero P. Gonelli A. Mirandola P. Melloni E. Zamai L. Celeghini C. Milani D. Zauli G. Blood. 2002; 100: 2421-2429Crossref PubMed Scopus (81) Google Scholar). Here we describe for the first time that TRAIL is able to induce proliferation of RA FLS. A previous study analyzed the effect of TRAIL on RA FLSs for shorter culturing periods, i.e. up to 24 h, and reported the induction of apoptosis (9Ichikawa K. Liu W. Fleck M. Zhang H. Zhao L. Ohtsuka T. Wang Z. Liu D. Mountz J.D. Ohtsuki M. Koopman W.J. Kimberly R. Zhou T. J. Immunol. 2003; 171: 1061-1069Crossref PubMed Scopus (94) Google Scholar). Varying levels of apoptosis were induced by TRAIL on the different RA FLS cultures tested in which a portion of cells survived (9Ichikawa K. Liu W. Fleck M. Zhang H. Zhao L. Ohtsuka T. Wang Z. Liu D. Mountz J.D. Ohtsuki M. Koopman W.J. Kimberly R. Zhou T. J. Immunol. 2003; 171: 1061-1069Crossref PubMed Scopus (94) Google Scholar). These RA FLSs strongly express TRAIL-R2 and were highly susceptible to an agonistic anti-TRAIL-R2 antibody, identifying TRAIL-R2 as the receptor mediating TRAIL-induced apoptosis (9Ichikawa K. Liu W. Fleck M. Zhang H. Zhao L. Ohtsuka T. Wang Z. Liu D. Mountz J.D. Ohtsuki M. Koopman W.J. Kimberly R. Zhou T. J. Immunol. 2003; 171: 1061-1069Crossref PubMed Scopus (94) Google Scholar). In agreement with these observations, Miranda-Carus et al. analyzed (10Miranda-Carus M.E. Balsa A. Benito-Miguel M. De Ayala C.P. Martin-Mola E. Arthritis Rheum. 2004; 50: 2786-2793Crossref PubMed Scopus (39) Google Scholar) fibroblasts of 50 RA synovial fluid samples and found that about half of them express functionally active TRAIL-R2. These cells underwent apoptosis when treated in vitro with an agonistic anti TRAIL-R2 antibody (10Miranda-Carus M.E. Balsa A. Benito-Miguel M. De Ayala C.P. Martin-Mola E. Arthritis Rheum. 2004; 50: 2786-2793Crossref PubMed Scopus (39) Google Scholar). Although these reports suggested the specific targeting of TRAIL-R2 on RA FLSs as a potential therapeutical approach, Perlman et al. drew the opposite conclusion because they could not detect the expression of TRAIL-R1 or TRAIL-R2 or the susceptibility to TRAIL in RA FLSs (11Perlman H. Nguyen N. Liu H. Eslick J. Esser S. Walsh K. Moore T.L. Pope R.M. Arthritis Rheum. 2003; 48: 3096-3101Crossref PubMed Scopus (28) Google Scholar). A possible explanation for these contradictory observations might be the use of different protocols to isolate and/or culture RA fibroblasts. The results described here suggest two distinct types of modulation of RA fibroblasts by TRAIL. TRAIL induced rapid cytotoxicity in a subset of RA FLSs that was followed by an induction of proliferation in the surviving cells. This proliferative effect appears to be mainly mediated by TRAIL-R2, because an agonistic anti TRAIL-R2 antibody induced proliferation of RA FLS in a similar manner as that of recombinant TRAIL. Therefore, it emerges that TRAIL can promote both proliferation as well as apoptosis, as has been established for other members of the TNF family (26Screaton G. Xu X.N. Curr. Opin. Immunol. 2000; 12: 316-322Crossref PubMed Scopus (97) Google Scholar). For example, Fas ligand/receptor interaction stimulates T cells during the early activation phase, whereas it mediates apoptosis at later phases of T cell activation (27Suzuki I. Fink P.J. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 1707-1712Crossref PubMed Scopus (104) Google Scholar). We show here that TRAIL promotes cell proliferation by activation of the MAP kinases ERK1/2 and p38 and the serine/threonine kinase Akt. While this manuscript was under preparation, Myashita et al. reported that TRAIL activates ERK1/2 and Akt in RA FLSs, preventing these cells from undergoing apoptosis (28Miyashita T. Kawakami A. Tamai M. Izumi Y. Mingguo H. Tanaka F. Abiru S. Nakashima K. Iwanaga N. Aratake K. Kamachi M. Arima K. Ida H. Migita K. Origuchi T. Tagashira S. Nishikaku F. Eguchi K. Biochem. Biophys. Res. Commun. 2003; 312: 397-404Crossref PubMed Scopus (48) Google Scholar). The ERK1/2 and PI3 kinase/Akt pathways have been reported to activate NFκB, and, in certain cell types, TRAIL has been reported to activate NFκB via ligation of TRAIL-R1 (29Hu W.H. Johnson H. Shu H.B. J. Biol. Chem. 1999; 274: 30603-30610Abstract Full Text Full Text PDF PubMed Scopus (206) Google Scholar). We could, however, detect no activation of NFκB in RA FLSs by TRAIL. Notably, very similar observations were made in a different cellular system (8Secchiero P. Gonelli A. Carnevale E. Milani D. Pandolfi A. Zella D. Zauli G. Circulation. 2003; 107: 2250-2256Crossref PubMed Scopus (259) Google Scholar) where TRAIL promoted the proliferation of primary human vascular endothelial cells (HUVECs) by activating the ERK1/2 and Akt but not the NFκB pathways. These data suggest that TRAIL promotes cell growth through an NFκB-independent mechanism. The inhibition of MAP kinases abrogated TRAIL-mediated RA FLS proliferation partially, and the inhibition of PI3 kinase abrogated it completely, confirming that both pathways are essential for RA FLS proliferation. Different regulatory pathways have been proposed to control the sensitivity of RA FLSs toward apoptotic signals. These include altered expression levels of apoptosis inhibitory proteins such as FLIP and Bcl-2 (30Schedel J. Gay R.E. Kuenzler P. Seemayer C. Simmen B. Michel B.A. Gay S. Arthritis Rheum. 2002; 46: 1512-1518Crossref PubMed Scopus (80) Google Scholar, 31Palao G. Santiago B. Galindo M. Paya M. Ramirez J.C. Pablos J.L. Arthritis Rheum. 2004; 50: 2803-2810Crossref PubMed Scopus (53) Google Scholar) and the over-activation of MAP and PI3 kinases (18Firestein G.S. Manning A.M. Arthritis Rheum. 1999; 42: 609-621Crossref PubMed Scopus (178) Google Scholar, 32Zhang H.G. Wang Y. Xie J.F. Liang X. Liu D. Yang P. Hsu H.C. Ray R.B. Mountz J.D. Arthritis Rheum. 2001; 44: 1555-1567Crossref PubMed Scopus (114) Google Scholar). These kinases have been shown to be activated by pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-18, which are present at elevated levels in the joints of arthritis patients (17Reddy S.A. Huang J.H. Liao W.S. J. Biol. Chem. 1997; 272: 29167-29173Abstract Full Text Full Text PDF PubMed Scopus (219) Google Scholar, 32Zhang H.G. Wang Y. Xie J.F. Liang X. Liu D. Yang P. Hsu H.C. Ray R.B. Mountz J.D. Arthritis Rheum. 2001; 44: 1555-1567Crossref PubMed Scopus (114) Google Scholar, 33Morel J.C. Park C.C. Woods J.M. Koch A.E. J. Biol. Chem. 2001; 276: 37069-37075Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar). The present study suggests that TRAIL stimulation may contribute to survival/proliferation by inducing Akt and ERK1/2. In accordance with this idea, RA FLS proliferation is enhanced by the combined addition of IL-1β and TRAIL. There is some precedent for TRAIL having both apoptotic and proliferative functions. Treatment of the promyelocytic human HL-60 cell line with TRAIL resulted in rapid cytotoxicity within 6–24 h, followed by progressive maturation of the surviving cells along the monocytic lineage (25Secchiero P. Gonelli A. Mirandola P. Melloni E. Zamai L. Celeghini C. Milani D. Zauli G. Blood. 2002; 100: 2421-2429Crossref PubMed Scopus (81) Google Scholar). The capacity of TRAIL to sequentially induce death and growth signals in one cell type might therefore be a common mode of function. Consequently, the stimulatory effect of TRAIL observed on RA FLS complicates the proposed strategy to use TRAIL for targeting RA FLS. On the other hand, our results suggest Akt is a potential target to block joint destruction in RA. We thank Dr. Valérie Pinet for helpful discussion, Dr. Planelles for help with fluorescence-activated cell sorter analysis, and Dr. Hipskind for critical reading of the manuscript. We thank Professors Canovas and Chammas and Dr. Coulet for providing synovial tissues." @default.
• W1965718993 created "2016-06-24" @default.
• W1965718993 creator A5001363237 @default.
• W1965718993 creator A5008811878 @default.
• W1965718993 creator A5009430102 @default.
• W1965718993 creator A5022109878 @default.
• W1965718993 date "2005-04-01" @default.
• W1965718993 modified "2023-10-09" @default.
• W1965718993 title "Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Rheumatoid Arthritis Synovial Fibroblast Proliferation through Mitogen-activated Protein Kinases and Phosphatidylinositol 3-Kinase/Akt" @default.
• W1965718993 cites W1530717069 @default.
• W1965718993 cites W1964857530 @default.
• W1965718993 cites W1970431545 @default.
• W1965718993 cites W1970856815 @default.
• W1965718993 cites W1973158357 @default.
• W1965718993 cites W1979758455 @default.
• W1965718993 cites W1980919524 @default.
• W1965718993 cites W1998650748 @default.
• W1965718993 cites W2006288082 @default.
• W1965718993 cites W2016085791 @default.
• W1965718993 cites W2021323060 @default.
• W1965718993 cites W2029962300 @default.
• W1965718993 cites W2041327426 @default.
• W1965718993 cites W2048782984 @default.
• W1965718993 cites W2052300492 @default.
• W1965718993 cites W2057698452 @default.
• W1965718993 cites W2058400117 @default.
• W1965718993 cites W2060960232 @default.
• W1965718993 cites W2062704228 @default.
• W1965718993 cites W2066776411 @default.
• W1965718993 cites W2066868766 @default.
• W1965718993 cites W2078532650 @default.
• W1965718993 cites W2080499713 @default.
• W1965718993 cites W2081529758 @default.
• W1965718993 cites W2087596041 @default.
• W1965718993 cites W2093910167 @default.
• W1965718993 cites W2099516468 @default.
• W1965718993 cites W2109587559 @default.
• W1965718993 cites W2130988210 @default.
• W1965718993 cites W2131207360 @default.
• W1965718993 cites W2142790993 @default.
• W1965718993 cites W2152348310 @default.
• W1965718993 cites W2161633444 @default.
• W1965718993 doi "https://doi.org/10.1074/jbc.m414469200" @default.
• W1965718993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15684417" @default.
• W1965718993 hasPublicationYear "2005" @default.
• W1965718993 type Work @default.
• W1965718993 sameAs 1965718993 @default.
• W1965718993 citedByCount "158" @default.
• W1965718993 countsByYear W19657189932012 @default.
• W1965718993 countsByYear W19657189932013 @default.
• W1965718993 countsByYear W19657189932014 @default.
• W1965718993 countsByYear W19657189932015 @default.
• W1965718993 countsByYear W19657189932016 @default.
• W1965718993 countsByYear W19657189932017 @default.
• W1965718993 countsByYear W19657189932018 @default.
• W1965718993 countsByYear W19657189932019 @default.
• W1965718993 countsByYear W19657189932020 @default.
• W1965718993 countsByYear W19657189932021 @default.
• W1965718993 countsByYear W19657189932023 @default.
• W1965718993 crossrefType "journal-article" @default.
• W1965718993 hasAuthorship W1965718993A5001363237 @default.
• W1965718993 hasAuthorship W1965718993A5008811878 @default.
• W1965718993 hasAuthorship W1965718993A5009430102 @default.
• W1965718993 hasAuthorship W1965718993A5022109878 @default.
• W1965718993 hasBestOaLocation W19657189931 @default.
• W1965718993 hasConcept C124160383 @default.
• W1965718993 hasConcept C132149769 @default.
• W1965718993 hasConcept C17991360 @default.
• W1965718993 hasConcept C184235292 @default.
• W1965718993 hasConcept C185592680 @default.
• W1965718993 hasConcept C190283241 @default.
• W1965718993 hasConcept C203014093 @default.
• W1965718993 hasConcept C2777575956 @default.
• W1965718993 hasConcept C2780610907 @default.
• W1965718993 hasConcept C502942594 @default.
• W1965718993 hasConcept C55493867 @default.
• W1965718993 hasConcept C71924100 @default.
• W1965718993 hasConcept C75217442 @default.
• W1965718993 hasConcept C86803240 @default.
• W1965718993 hasConcept C90934575 @default.
• W1965718993 hasConcept C95444343 @default.
• W1965718993 hasConcept C97029542 @default.
• W1965718993 hasConceptScore W1965718993C124160383 @default.
• W1965718993 hasConceptScore W1965718993C132149769 @default.
• W1965718993 hasConceptScore W1965718993C17991360 @default.
• W1965718993 hasConceptScore W1965718993C184235292 @default.
• W1965718993 hasConceptScore W1965718993C185592680 @default.
• W1965718993 hasConceptScore W1965718993C190283241 @default.
• W1965718993 hasConceptScore W1965718993C203014093 @default.
• W1965718993 hasConceptScore W1965718993C2777575956 @default.
• W1965718993 hasConceptScore W1965718993C2780610907 @default.
• W1965718993 hasConceptScore W1965718993C502942594 @default.
• W1965718993 hasConceptScore W1965718993C55493867 @default.
• W1965718993 hasConceptScore W1965718993C71924100 @default.
• W1965718993 hasConceptScore W1965718993C75217442 @default.
• W1965718993 hasConceptScore W1965718993C86803240 @default.
• W1965718993 hasConceptScore W1965718993C90934575 @default.
• W1965718993 hasConceptScore W1965718993C95444343 @default.

• next